Ratings Jafron Biomedical Co.,Ltd.

Equities

300529

CNE100002995

End-of-day quote Shenzhen S.E. Other stock markets 06:00:00 2024-05-23 pm EDT			5-day change	1st Jan Change
28.05 ^CNY	-0.21%		-3.04%	+26.18%

May. 24	Jafron Biomedical Co.,Ltd. Announces Final Dividend on A Shares for 2023, Payable on 31 May 2024	CI
Apr. 26	Jafron Biomedical Co.,Ltd. Proposes Final Dividend for the Year 2023	CI

Summary

Overall, and from a short-term perspective, the company presents an interesting fundamental situation.
The company's Refinitiv ESG score, based on a relative ranking of the company within its sector, comes out particularly poor.

Strengths

The prospective high growth for the next fiscal years is among the main assets of the company
The company's profit outlook over the next few years is a strong asset.
The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
Over the last 4 months, analysts have significantly revised upwards the company's estimated sales.
Analysts remain confident with respect to the group's activity and, more often than not, have revised upwards their earnings per share estimates.
Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Over the past four months, analysts' average price target has been revised upwards significantly.
The opinion of analysts covering the stock has improved over the past four months.
Considering the small differences between the analysts' various estimates, the group's business visibility is good.
Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.

Weaknesses

The company benefits from high valuations in earnings multiples.
The company appears highly valued given the size of its balance sheet.
For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Medical Equipment, Supplies & Distribution

	1st Jan change	Capi.	ESG Refinitiv
JAFRON BIOMEDICAL CO.,LTD.	+26.18%	3B	D+
ABBOTT LABORATORIES	-5.56%	181B	C+
MEDTRONIC PLC	-0.11%	108B	C
BECTON, DICKINSON AND COMPANY	-6.17%	66.12B	A
DEXCOM, INC.	+2.64%	50.65B	B-
CENCORA, INC.	+6.58%	43.66B	B-
HOYA CORPORATION	+4.91%	41.3B	B+
METTLER-TOLEDO INTERNATIONAL, INC.	+21.98%	31.6B	B
TERUMO CORPORATION	+14.45%	25.03B	A-
WEST PHARMACEUTICAL SERVICES, INC.	-5.81%	24.16B	A-

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes